Butyrolactone I | 1690

Cell permeable. A potent and selective inhibitor of the cyclin-dependent kinases CDK1/cyclin B, CDK2 and CDK5. Inhibits cell cycle progression at the G1/S and G2/M transitions. BLI is an important tool for probing the cellular roles of CDKs. It blocks Fas-induced apoptosis and displays antitumor activity.

Butyrolactone I is a potent and selective inhibitor of the cyclin-dependent kinases CDK1/cyclin B, CDK2 and CDK5. Inhibits cell cycle progression at the G1/S and G2/M transitions.

1690 | Butyrolactone I DataSheet

Alternate Name/Synonyms: BLI, BL-I

Appearance: White solid

Formulation: N/A

CAS Number: 87414-49-1

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₂₄H₂₄O₇

Molecular Weight: 424.44

Cell-Permeable?: Yes

Purity: ≥99% by HPLC

Solubilities: DMSO (10 mg/ml) and Ethanol (25 mg/ml)

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A CDK inhibitor

MDL Number: MFCD03453074

PubChem CID: 3035414

SMILES: CC(=CCC1=C(C=CC(=C1)COC(=O)C2(C(=C(C(=O)O2)O)C3=CC=C(C=C3)O)C)O)C

InChi: InChI=1S/C24H24O7/c1-14(2)4-6-17-12-15(5-11-19(17)26)13-30-23(29)24(3)20(21(27)22(28)31-24)16-7-9-18(25)10-8-16/h4-5,7-12,25-27H,6,13H2, 1-3H3/t24-/m1/s1

InChi Key: FPVUCBMBMUHRDX-XMMPIXPASA-N